By Chris Wack
Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded data from an ongoing Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
The biopharmaceutical company said the panel, consisting of experts in pulmonary diseases and biostatistics, will provide an independent recommendation to Pliant regarding the trial.
The panel will serve as part of an expanded DSMB with the goal to reach a consensus recommendation regarding the trial. The decision to assemble the outside panel was taken as the company hasn't been able, through review of blinded data, to determine the rationale for the DSMB's recommendation to pause enrollment and dosing in the trial.
Pliant expects this process to conclude in two to four weeks.
Following the DSMB's previously announced recommendation, Pliant voluntarily paused enrollment and dosing in the clinical trial. Pliant said it will continue to remain blinded in order to ensure data integrity of the clinical trial with the goal of maintaining its potential to serve as a registrational trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 13, 2025 10:27 ET (15:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。